Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa

J; Kalua, K; Mrango, Z; Ray, KJ; Cook, C; Lebas, E; O’Brien, KS; Emerson, PM; Porco, TC; Lietman, TM; MORDOR Study Group, ; , COLLABORATORS; Doan, T; Oldenburg, CE; Cotter, SY; Stoller, NE; Vanderschelden, B; Fry, DM; Rosenthal, PJ; Rutherford, GW; Zhou, Z; Zhong, L; Gaynor, BD; Whitcher, JP; Mabey, DCW; Burr, SE; Solomon, AW; Dreger, K; Munoz, B; Coles, CL; Labrique, AB; Sommer, A; Kaur, H; Bloch, EM; Chisambi, A; Kamwendo, Z; Maleta, K; Callahan, EK; Stewart, AE; Kane, S; Abdou, A; Kadri, B; Beido, N; Kasubi, M; Mboera, L (2018) Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. The New England journal of medicine, 378 (17). pp. 1583-1592. ISSN 0028-4793 DOI: https://doi.org/10.1056/NEJMoa1715474

[1]  P. J. Hooper,et al.  Progress and projections in the program to eliminate trachoma , 2017, PLoS neglected tropical diseases.

[2]  Ellen K. Silbergeld,et al.  Longitudinal Comparison of Antibiotic Resistance in Diarrheagenic and Non-pathogenic Escherichia coli from Young Tanzanian Children , 2016, Front. Microbiol..

[3]  A. Escribano,et al.  Lack of effect of azithromycin on QT interval in children: a cohort study , 2016, Archives of Disease in Childhood.

[4]  T. Porco,et al.  The Effect of Mass Azithromycin Distribution on Childhood Mortality: Beliefs and Estimates of Efficacy. , 2015, The American journal of tropical medicine and hygiene.

[5]  N. Grassly,et al.  Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma , 2015, Journal of tropical medicine.

[6]  M. Eberly,et al.  Azithromycin in Early Infancy and Pyloric Stenosis , 2015, Pediatrics.

[7]  B. Munoz,et al.  Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. , 2014, International journal of epidemiology.

[8]  Bjoern Peters,et al.  Advances in infantile hypertrophic pyloric stenosis , 2014, Expert review of gastroenterology & hepatology.

[9]  E. Shutes,et al.  Prioritizing Countries for Interventions to Reduce Child Mortality: Tools for Maximizing the Impact of Mass Drug Administration of Azithromycin , 2014, PloS one.

[10]  P. Rosenthal,et al.  Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial. , 2014, The American journal of tropical medicine and hygiene.

[11]  B. Feenstra,et al.  Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study , 2014, BMJ : British Medical Journal.

[12]  H. Svanström,et al.  Use of azithromycin and death from cardiovascular causes. , 2013, The New England journal of medicine.

[13]  C Michael Stein,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[14]  B. Munoz,et al.  Mass Distribution of Azithromycin for Trachoma Control Is Associated With Short-term Reduction in Risk of Acute Lower Respiratory Infection in Young Children , 2012, The Pediatric infectious disease journal.

[15]  B. Munoz,et al.  Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. , 2011, The American journal of tropical medicine and hygiene.

[16]  T. Gebre,et al.  Childhood mortality in a cohort treated with mass azithromycin for trachoma. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  T. Gebre,et al.  Antibiotic Selection Pressure and Macrolide Resistance in Nasopharyngeal Streptococcus pneumoniae: A Cluster-Randomized Clinical Trial , 2010, PLoS medicine.

[18]  T. Gebre,et al.  Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. , 2009, JAMA.

[19]  T. Gebre,et al.  Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial , 2009, The Lancet.

[20]  M. Srinivasan,et al.  Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. , 2006, JAMA.

[21]  厚子 向田.  The New England Journal of Medicine における被訂正論文のインパクト , 2004 .

[22]  A. Schuchat,et al.  Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  C. Whitty,et al.  Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. , 1999, The Pediatric infectious disease journal.

[24]  T. Quinn,et al.  Azithromycin in control of trachoma , 1999, The Lancet.

[25]  J. Mathews,et al.  A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  R Peto,et al.  Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.

[27]  S. Kripalani,et al.  Adult Mortality in a Randomized Trial of Mass Azithromycin for Trachoma , 2013 .

[28]  R. Louie.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[29]  R. Black,et al.  Journal of Health Global , 2022 .